Date: 2013-07-12 14:25:45

Antidotes

Chelating agents

Anemias

Deferasirox

Triazoles

Thalassemia

Myelodysplastic syndrome

Chelation therapy

Iron overload

Medicine

Chemistry

Health

APPROVAL WITH CONDITIONS OF PrEXJADE* (deferasirox) 125 MG, 250 MG, & 500 MG DISPERSIBLE TABLETS FOR ORAL SUSPENSION FOR USE IN THE MANAGEMENT OF CHRONIC IRON OVERLOAD IN PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIAS AGED

Document is deleted from original location.
Use the Download Button below to download from the Web Archive.

File Size: 153,68 KB